ERBB2 and triple-negative breast carcinoma: The most common phenotype at diagnosis was HR + HER2- (57.7%), followed by triple-negative breast cancer (TNBC)(13.2%), showing a similar pattern after neoadjuvant therapy (NAT); HR + HER- (61.7%), and TNBC (16.3%).